Background:
The impact of the disease-free interval (DFI) on survival after a locoregional recurrence (LRR) or second primary breast cancer is uncertain. We aim to clarify this association using the Netherlands Cancer Registry.
Methods: Women first diagnosed with early breast cancer from 2003 to 2006 were selected from the Netherlands Cancer Registry. Follow-up was complete until the 1st January 2013. First or synchronous LRRs and second primary tumours in the first five years after the initial diagnosis were examined. The five-year period was divided into three equal intervals. Prognostic significance of the DFI on overall survival was determined in a univariate analysis using the log-rank test and Kaplan-Meier estimates. Survival after recurrence was examined with multivariate Cox regression analysis to control for confounding. Overall survival was compared for women with and without a LRR or second primary tumour.
Results: In total 36,255 women were included in the analysis. Disease recurrence occurred in 1,666 (4.6%) patients: 611 women developed a local recurrence, 224 a regional recurrence, 745 second primary breast cancer, and 86 a combination of recurrences. In the univariate analysis DFI resulted significant differences for both LRR and second primary tumours (P = 0.001 and P < 0.001 respectively). Longer DFI was associated with better survival after LRRs; no significant association was found in the Cox regression analysis for DFI and survival after second primary tumours (table) . Important covariates associated with higher survival rates were age <70 years and surgical removal of the recurrence. Conclusions: This is the first study to explore the relation between DFI and survival in a nation-wide population registry and it contributes to insight in prognosis after breast cancer recurrence. The DFI with regard to a LRR is an independent predictor of survival, with a longer interval resulting in longer survival.
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Poster The 'FFORESTS' project: First FOrum and REgistration STudy of Secondary breast cancer: A novel concept in the data collection and management of secondary breast cancer Background: In March 2010, the Velindre cancer centre in Cardiff, UK, set up the FFORESTS project. This is the first forum and registration prospective study of new cases of Secondary breast cancer in the UK. Methods: Patients living within of South East Wales who are newly diagnosed with secondary breast cancer are discussed within a multidisciplinary forum. The membership of the forum consists of: all the breast oncologists within the cancer centre and their teams, breast oncology nurse specialists, oncoradiologist, palliative care, clinical trial nurses, pharmacist and a therapeutic radiographer. Each case is discussed following a review of the history, biology and radiology and a management plan is recorded. Demographic data on the early breast cancer diagnosis where available including adjuvant therapy received, is documented. Other relevant factors recorded include performance status, referral to palliative medicine, and the pathology results including where rebiopsies are performed. The FFOREST project aims to collect prospective data on secondary breast cancer including incidence and prevalence and the overall survival of this population.
Results: There are more than 500 cases of newly diagnosed secondary breast cancer registered so far. The initial analysis of the first 12 months data is summarised here. The 3 year data will be available for presentation at this conference. From March 2010 to March 2011, 138 patients were identified, 37 (27%) who were denovo metastatic breast cancer. All patients were female with an mean age of 62 yrs (range 27−86). ER status was known in 95% of cases. 100 (73%) of these were ER positive and 32 (23%) were ERnegative. Her2 status was either obtained on the original primary tumour or where possible on a biopsy of the metastatic deposit. 40 (29%) of all cases were found to be Her2 positive whilst 17 (12%) of all cases were classed as triple negative.
The most common presentation of metastatic disease were at multiple sites (47%) and bone only (29%). Most patients were of good performance status (PS): PS0 (42%), PS1 (29%), PS2 (19%), PS3 (12%). Chemotherapy was used first line in 73 cases (52%) whilst endocrine therapy was used first line in 60 cases (43%).
Overall survival was calculated from the date of diagnosis of metastatic disease to the date of death or censored at the time of final analysis. The median overall survival for this population was 20 months. Within the different biological groups, the Her2 positive population appear to have the best median overall survival at 31.1 months. The cases with a PS0 at presentation also have a similar median overall survival at 29.9 months.
Conclusion: The FFOREST project is succesfully coordinating the care of secondary whilst collecting invaluable statistics on this complex patient group. The completion of the 3 year analysis will provide accurate prospective data for this group which is lacking in the UK. These results will undoubtedly inform future studies and a multicentre FFOREST project is proposed as a next step. (IDC) . Therefore, we hypothesized that with the introduction of SNB, stage migration will be more pronounced in ILC than in IDC.
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Material and Methods:
Women with primary non-metastatic T1 and T2 IDC or ILC, diagnosed between 1995 and 2010, were selected from the Netherlands Cancer Registry. Information on axillary lymph node status was collected and defined as: negative, isolated tumour cells (ITC), micrometastases or macrometastases. Of note, ITC were first documented in 2003. Logistic regression analysis was performed to determine the probability of having ITC, micrometastases or macrometastases, adjusting for method of staging, period, age at time of diagnosis, tumour size and grade.
Results: In total 131,295 patients were treated for IDC (89%) or ILC (11%). The percentage of patients staged with SNB gradually increased from 0% in 1995 to 72% in 2010. The percentage of patients with micrometastases increased from 1.4% in 1995 to 7.5% in 2010 for patients with IDC, and from 1.0% in 1995 to 5.6% in 2010 for patients with ILC (p < 0.0001). The incidence of ITC in patients with IDC increased from 1.8% in 2003 to 3.9% in 2010 (p < 0.0001). In patients with ILC the percentage of ITCs increased from 3.7% in 2003 to 7.7% in 2010 (p < 0.0001). Logistic regression analyses showed that women diagnosed in the period 1999-2002, 2003-2006 and 2007-2010 had a 3.0 times higher risk of having micrometastases compared to women in period 1995-1998. Patients with ILC had a 1.8 (95% CI 1.6−2.1) times higher risk of ITCs compared to patients with IDC. Risks were not elevated for the risk of having micro-or macrometastases when comparing ILC with IDC, with OR of 0.94 (0.87-1.03) and 0.94 (0.91-0.98), respectively.
Conclusion:
The introduction of SNB has led to stage migration due to a higher detection rate of micrometastases. Patients with ILC were more likely to have ITC than those with IDC.
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Poster Prognosis of metastatic breast cancer: Differences between patients with de novo and recurrent metastatic breast cancer V.C.G. [2007] [2008] [2009] in eight hospitals in the South-East of the Netherlands were included and categorized based on MFI. Survival was estimated using the Kaplan-Meier method. Cox proportional hazards model was used to determine the prognostic impact of de novo metastatic breast cancer (MFI <3 months) versus recurrent metastatic breast cancer (MFI 3−24 months and >24 months), adjusted for age, hormone receptor and HER2 status, initial site of metastases and use of prior adjuvant systemic therapy.
Results: A total of 815 patients were included; 154 (19%) patients with de novo metastatic breast cancer, 176 patients with MFI between 3 and 24 months and 485 patients with MFI >24 months. Median survival of patients with de novo metastatic breast cancer was 29.4 months which was comparable with the median survival of patients with recurrent metastatic breast cancer with MFI >24 months (median, 27.9 months, P = 0.73) but significantly better compared with patients with a distant recurrence between 3 and 24 months (median, 9.1 months, P < 0.0001). In multivariable analysis, MFI significantly influenced outcome for metastatic breast cancer with a hazard ratio (HR) for mortality of 1.93 (95% CI 1.45-2.58, P < 0.001) for recurrent metastatic breast cancer with MFI S73 between 3−24 months as compared with de novo metastatic breast cancer. Prognosis of patients with a MFI >24 months did not significantly differ from that of patients with de novo metastatic breast cancer (HR 0.90; 95% CI 0.70-1.15, P = 0.78). The association between MFI and survival was seen irrespective of use of adjuvant systemic therapy.
Conclusions:
The prognosis of patients with de novo metastatic breast cancer was comparable to the outcome of patients with recurrent metastatic breast cancer with a MFI of more than 24 months but significantly better when compared with those with a MFI between 3 and 24 months, irrespective of use of prior adjuvant systemic therapy.
Background: Nodal status in primary breast cancer is an important risk factor for distant recurrences. Its association with locoregional and contralateral breast cancer, however, is less well established. In this study the effect of nodal status on locoregional recurrence, distant recurrence, and contralateral breast cancer was assessed in a large population-based breast cancer registry.
Material and Methods: All early breast cancer patients (pT1−2, any N, M0) diagnosed and operated between 2003-2006 were selected from the Netherlands Cancer Registry. Patients without follow up were excluded. The five-year cumulative risk of developing locoregional (ipsilateral breast and locoregional lymph nodes) recurrence, distant recurrence, and contralateral breast cancer was calculated for various degrees of regional lymph node involvement: pN0, pN0(i+), pN1mi and pN1A.
Results: A total of 35,006 patients was identified. As expected the risk of distant recurrence increased with higher nodal status: 5.6%, 7.3%, 7.3% and 15.9% in N0, N0(i+), N1mi and N1A, respectively (see table) . Overall, locoregional recurrence and contralateral breast cancer rates were comparable at 2−3%. Locoregional recurrence was not associated with nodal status. The risk of developing contralateral breast cancer, however, decreased with more extensive nodal involvement: 3.1%, 2.9%, 2.3%, and 1, 5% in N0, N0(i+), N1mi and N1A, respectively.
Conclusion: Locoregional recurrence rates after breast cancer treatment is very low and is comparable to the risk of developing contralateral breast cancer. The risk of contralateral breast cancer is inversely related to the nodal involvement of the primary tumour. This phenomenon may well reflect the higher proportion of patients receiving systemic treatment in case of nodal involvement. Introduction: Predictive models are an integral part of clinical practice and can help determine optimal treatment strategies for individual patients. However, a drawback of available models is that covariates are assumed to have a constant effect on overall survival (OS), while the effect of certain covariates on OS may change over time (dynamic). Patients may experience treatment-or disease-related events (early treatment discontinuation, relapse), resulting in an altered prognosis from that time onwards. Available models may thus not accurately reflect a patient's OS probability over time. We investigated time-varying effects of patient-and tumor-related factors and developed a nomogram enabling dynamic calculation of the 5-year OS probability in endocrine sensitive, postmenopausal breast cancer (BC) patients at any timepoint (prediction timepoint, tp) up to 3 years after diagnosis. Methods: Dutch and Belgian postmenopausal endocrine sensitive early BC patients enrolled in the TEAM trial were allotted 5 years of exemestane alone or 2.5−3 years of tamoxifen followed by 2.5−2 years of exemestane. We assessed the time-varying effects of various covariates and obtained the dynamic predictions of the 5-year OS probability using a proportional baselines landmark supermodel. Covariates were age at diagnosis, histological grade (Bloom & Richardson), tumor size, nodal stage, locoregional recurrence, HER2 status and treatment compliance. We designed a nomogram to calculate a patient's OS probability based on patient characteristics and time-varying variables.
Results: A total of 2602 patients were included (median age 64 years, range 38−92). Mean follow-up was 6.1 years. Locoregional recurrence, high-risk nodal stage (N2/N3) and HER2 positivity demonstrated a change in effect on OS at different tps during follow-up (time-varying effect) (Figure 1 ). Based on our model, the hazard ratio (HR) for locoregional recurrence at a certain tp after the start of treatment was HR = 8.43·0.58 tp .
Similarly, for N2/N3 and HER2 positive patients, HR = 3.62·0.82 tp and HR = 1.24·0.85
tp . All other covariates showed time-constant effects.
Conclusion:
The nomogram predicts an individual's 5-year OS probability over time, accounting for elapsed time and status change since primary diagnosis, revealing that prognosis varies during follow-up. With longer follow-up, this model can help determine the necessity of continuing (extended) adjuvant endocrine therapy at different points in time. 5-year dynamic survival probability is calculated by taking the sum of the risk points, which are determined by the individual's patient-, tumor-, and treatment-specific characteristics. Dynamic 5-year overall survival probability can be calculated by taking the sum of the risk points, which are determined by the individual's patient-, tumor-, and treatment-specific characteristics. A number of risk points are assigned to each specific covariate that corresponds with the patient's individual characteristic. (between 1991 and 1996) and 2004. Women were aged 39−41 years at entry. For every case, five controls were selected through incidence density sampling. All trial cases were included in screening invitation (intention-totreat) analyses (356 cases, 1780 controls), whereas analyses on screening attendance (per-protocol) were restricted to women invited to screening (105 cases, 525 age-matched controls). Conditional logistic regression was used to estimate odds ratios (OR) and corresponding 95% confidence intervals (CI). The ORs were adjusted for self-selection bias.
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Results: Screening invitation resulted in a non-significant breast cancer mortality reduction of 17% in the case-control analyses, similar to full trial results. The analyses on attendance showed that the screening effect greatly depends on the definition of screening exposure and adjustments for self-selection bias. Having ever attended a screening exam only appeared to have some effect after adjustment for self-selection (OR 0.86, 95% CI 0.39-1.94), whereas recent attendance resulted in an adjusted mortality reduction of 36% (OR 0.64, 95% CI 0.31−1.31).
Conclusions: Differences in study design should be taken into account when comparing studies on breast cancer screening effect. Screening policies have to be based on the most current and accurate benefit-risk ratios possible in order to obtain the maximum net benefit from screening. Future studies on screening effectiveness should therefore appropriately adjust for these potential biases. Results: A decreasing trend over time in axillary lymph node dissection (ALND) was seen in clinically node negative patients (cT1-2N0) toward less than 10%. In university hospitals ALND was performed the least in pN0 (i-) (6.6%). The percentage ALND after positive macro of micro metastasis in the SN decreased towards resp. 83% and 49%in 2011. The percentage ALDN after positive ITC decreased from 40% in 2006 to 4% in 2011. University and teaching hospitals were more likely than non-teaching hospitals to offer breast-conserving therapy to elderly patients. Regional differences were revealed in the percentage radical surgeries after first breast-conserving surgery in patients with invasive breast cancer (from 6.1% to 9.8%) and in patients with DCIS (from 28% to 31%).
Variation was also observed for the percentage adjuvant radiotherapy after breast-conserving surgery for DCIS, 77% versus 86% in both other hospital types. In patients with locally advanced breast cancer variation was seen in locoregional radiotherapy between regions from 76% to 84%.
Regional variation was observed in the use of neo-adjuvant chemotherapy for cT4 tumors, ranging between 60−80%. The use of adjuvant chemotherapy in patients younger than 60 years with node positive breast cancer (T1-2N1) varied between 85% and 95% between regions.
Conclusion: Variation in multidisciplinary treatment of breast cancer patients between hospital types and regions was revealed. Insight in the cause of this variation could give clues for future guideline implementation strategies.
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Poster New era of mutation screening in breast cancer using targeted next-generation sequencing Results: Data showed that next-generation sequencing was able to detect all 54 types of mutations (positive controls) that previously identified by Sanger sequencing. In cancer cohort, there were 59 missense variants of unknown significance detected, in which they were not listed in 1000Genome. With careful assessment, based on their absence in healthy controls and in silico prediction and analysis (SIFT, PolyPhen-2 and Align-GVGD), 12 of these variants were classified as deleterious.
Conclusions: Targeted next-generation sequencing is a powerful tool for mutation spectrum characterization. This platform cost less with a high turn over time, and with relatively low DNA input. Moreover, the capability to test more genes in one test is more feasible. This technology is the commencement of a new era in genetic testing and diagnostic settings.
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Poster Genetic variation in CYP19A1, daily estrogen level and mammographic density in premenopausal women 
S75
including eight common polymorphisms in CYP19A1. Daily salivary 17b-estradiol was measured throughout an entire menstrual cycle using validated methods. Computer assisted mammographic density (Madena) was obtained from digitized mammograms taken at days 7−12 of the menstrual cycle. The associations between genetic variations in CYP19A1, 17b-estradiol and mammographic density were studied in multivariable linear and logistic regression models.
Results:
The rs749292 minor alleles were associated with lower absolute mammographic density (b = −4.83, p = 0.032), and lower total breast area (b = −9.66, p = 0.024). Among lean women (BMI 23.6 kg/m 2 ), the risk of having absolute mammographic density >32.4 cm 2 was reduced by 78% in rs749292 heterozygote haplotype Aa, Odds Ratio (OR) 0.22, 95% CI 0.07−0.7, and by 74% in minor haplotype aa, OR 0.26, 95% CI 0.07-0.95. Similar findings were observed for this genetic variation in CYP19A1 and percent mammographic density in lean women. The negative association with mammographic density could not be explained by variation in daily 17b-estradiol. There was no association between rs749292 and mammographic density among women with BMI > 23.6 kg/m 2 . Conclusion: Our findings suggest an association between the single nucleotide polymorphism rs749292 in CYP19A1 and mammographic density in premenopausal women, not explained by cycling estradiol levels.
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Poster Birth weight, childhood BMI and height in relation to mammographic density and breast cancer: Register based cohort study Introduction: High breast density, a strong predictor of breast cancer risk, may be determined early in life. Childhood anthropometric factors have been related to breast cancer and breast density, but rarely simultaneously. We examine whether mammographic density (MD) mediates an association of birth weight, childhood body mass index (BMI) and height with the risk of breast cancer. Methods: 13,572 women (50−69 years) in the Copenhagen mammography screening program (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) with childhood anthropometric measurements in the Copenhagen School Health Records Register were followed for breast cancer until 2010. Using logistic and Cox regression models we investigated associations among birth weight, height and BMI at ages 7−13 with MD (mixed/dense or fatty) and breast cancer, respectively.
Results: 8,194 (60.4%) women had mixed/dense breasts and 716 (5.3%) developed breast cancer. Childhood BMI was significantly and inversely related to having mixed/dense breasts at all ages, with age at screening and birth cohort adjusted odds ratios (95% confidence intervals) ranging from 0.69 (0.66-0.72) at age 7 to 0.56 (0.53-0.58) at age 13, per one unit increase in z-score. No statistically significant associations were detected between birth weight and MD, height and MD, or birth weight and breast cancer risk. BMI was inversely associated to breast cancer risk, with age and birth cohort adjusted hazard ratios (HRs) of 0.91 (0.83-0.99) at age 7 and 0.92 (0.84-1.00) at age 13, whereas height was positively associated with breast cancer risk [age 7: 1.06 (0.98-1.14) and age 13: 1.08 (1.00-1.16)]. After additional adjustment for MD, associations of BMI with breast cancer risk diminished [age 7: 0.97 (0.88-1.06) and age 13: 1.01 (0.93-1.11)], but remained with height [age 7: 1.06 (0.99-1.15) and age 13: 1.09 (1.01−1.17)].
Conclusions: Among women 50 years and older, childhood body fatness reduces the breast cancer risk, possibly via a mechanism mediated by MD, at least in part. Childhood tallness increases breast cancer risk, seemingly via a pathway independent of MD. Birth weight was not associated with MD or breast cancer risk in this age group. Background: Trastuzumab has dramatically improved the outcome of HER2 positive breast cancer patients; however its uptake is not homogeneous across different European countries. The European Union (EU) has adopted a common procedure for drug approval, through the European Medicines Agency (EMA), for the granting marketing authorization for oncologic medicines in the EU countries. Nevertheless pricing and reimbursement decisions are a competency of EU national governments and these policies are diverse among the EU member states.
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We aim to evaluate the reimbursement times of trastuzumab in the EU countries and its association to health expenditure and wealth indicators, to health policy efficacy indicator, the availability of cost-effectiveness studies and finally to breast cancer outcome.
Material and Methods: Cancer indicators and health and wealth indicators were extracted from the World Health Organization and the World Bank databases. Breast cancer outcome was estimated by the mortality/ incidence (M/I) ratio. The Mackenbach score, used quantitatively and categorized (>50, 0−50, <0), was used as health policy efficacy indicator. The dates of reimbursement approval of trastuzumab were provided by Roche. The Spearman rank Correlation test, the Wilcoxon rank-sum test end and the Fisher exact test were used to evaluate associations and/or differences between these variables. Additional analyses were made by dichotomizing countries in groups according to compliance to the 180 days EU recommendation for drug reimbursement.
Results: A statistically significant inverse and strong correlation between breast cancer M/I ratio and health expenditure (rs = −0.730, p < 0.001) and the health policy performance (rs = −0.711, p < 0.001) was found, meaning the better the score and the higher the expenditure, the fewer patients die after a breast cancer diagnosis. Factors associated with compliance to the 180 days EU recommendation for trastuzumab reimbursement were better health policy score (100%, 85% and 25% respectively, p = 0.005), higher health expenditure (3631.7$ vs. 693.8$, p < 0.001) and availability of cost effectiveness studies (100% vs. 53%, p = 0.026).
Conclusions: Higher health policy score and health expenditure are related to faster reimbursement of trastuzumab and better breast cancer outcome. A marked difference is observed between Eastern and Western Europe, with long delays and increased breast cancer mortality identified in Eastern European countries.
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Poster The experience of high-risk patients in a breast cancer family history clinic in a district general hospital in the United Kingdom 
Material and Methods:
The clinic was originally set up with a research grant from the QUEST cancer research charity. Women with a family history of breast cancer were referred to this clinic by their general practitioner or breast clinician. Women were asked to complete a family history questionnaire. Originally in late 2006 these patient's pedigrees were handwritten, then entered onto Progeny software, but by August 2009 this was replaced by FaHRAS software which is still in use.
Using the NICE guidelines the women were categorised into population, moderate and high risk groups and managed accordingly.
Results: Between August 2009 and October 2013 a total of 1089 women have been assessed in the clinic. A further 50 patients were referred directly to the regional genetics service. 146 were declined at the initial triage stage as population risk. Of those seen, 218 (20%) are near population risk, 386 (35.4%) are moderate risk and 485 (44.5%) are high risk. A total of 436 women were referred to the regional genetics service. Of them, 118 were offered testing for the BRCA gene mutations. Of these, 106 have been tested, 43 BRCA1 or BRCA2 mutation carriers were identified, 37 tested negative and 19 were inconclusive.
Since testing positive for a BRCA mutation 7 women have undergone bilateral salpingo-oophorectomy (BSO) alone, 2 have had risk-reducing bilateral mastectomy (RRM) alone, and 5 have had both BSO and RRM.
Conclusion/Summary: • The family history clinic provides a comprehensive service to women with a breast cancer family history encompassing specialised risk analysis, clinical and radiological assessment and appropriate counselling.
• There is a high demand for this service in a district general hospital • A significant proportion of these women will require genetic counselling • A number of these women will go on to require further specialist management such as risk-reducing surgery. Background: Annual MRI and mammography is recommended for BRCA1 and BRCA2 mutation carriers to reduce breast cancer mortality. Less intensive screening is advised 60 years, although effectiveness is unknown.
References
Materials and Methods:
We identified BRCA1/2 mutation carriers without bilateral mastectomy before age 60 to determine for whom screening 60 is relevant, in the Rotterdam Family Cancer Clinic and HEBON: a nationwide prospective cohort study. Furthermore, we compared tumour stage at breast cancer diagnosis between different screening strategies in BRCA1/2 mutation carriers 60 with univariable analysis and multivariable logistic regression. Tumours >2 cm, positive lymph nodes, or distant metastases at detection were defined as 'unfavourable'.
Results: Of 548 BRCA1/2 mutation carriers 60 years in 2012, 395 (72%) did not have bilateral mastectomy before the age of 60. Of these 395, 224 (57%) had a history of breast or other invasive carcinoma. In 136 BRCA1/2 mutation carriers, we compared 148 breast cancers (including interval cancers) detected 60, of which 84 (57%) were first breast cancers. With biennial mammography 53% (30/57) of carcinomas were detected in unfavourable stage, compared to 21% (12/56) with annual mammography (adjusted odds ratio: 4.07, 95% confidence interval [1.79-9.28], p = 0.001). Moreover, with biennial screening 40% of breast cancers were interval cancers, compared to 20% with annual screening (p = 0.016). Results remained significant for BRCA1 and BRCA2 mutation carriers, and first breast cancers separately.
Conclusions: Over 70% of 60-year old BRCA1/2 mutation carriers remain at risk for breast cancer, of which half has prior cancers. When life expectancy is good, continuation of annual breast cancer screening of BRCA1/2 mutation carriers 60 is worthwhile.
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Poster Does digital mammography increase ductal carcinoma in situ detection rate? Trends after 7 years of digitalisation in Barcelona, Spain Background: The aim of this study was to explore trends of ductal carcinoma in situ (DCIS) and invasive breast cancer detection rates in initial and successive screenings in a cohort of women screened from 1996 to 2011, before and after the transition from screen-film mammography (SFM) to digital mammography (DM).
Material and Methods: We analyzed a retrospective cohort of screened women from a population-based screening program in Barcelona (Catalonia, Spain) screened from 1996 to 2011 (n = 58,647). A total of 198,989 screening mammograms were included in the analysis, 102,970 SFM and 96,019 DM. We divided the study period in 8 periods of 2 years, from 1996 to 2003 with SFM and form 2004 to 2011 with DM. Invasive and DCIS cancer detection rates per 1,000 mammograms were computed and compared among periods, using Chi-squared tests.
Results: An overall number of 910 breast tumors were detected in the study period. No statistically significant differences were observed in cancer detection rate comparing SFM and DM periods neither in initial (5.10‰ and 5.21‰ respectively, p = 0.580) nor in successive screenings (4.26‰ and 4.40‰ respectively, p = 0.679). However, rates of DCIS were higher in DM than in SFM period (0.80‰ and 0.56‰ respectively, p = 0.041) while invasive cancer rates were lower (3.70‰ and 3.95‰ in DM and SFM respectively, p = 0.350). The highest rate of DCIS was observed in initial screenings in the first DM period, followed by a decrease in the subsequent DM periods, from 0.14‰ to 0.02‰. In successive screenings, rates of DCIS were higher in the second and third DM periods (0.091‰ and 0.097‰) to decrease in the fourth one (0.06‰).
Conclusion: Some controversies have risen concerning the higher detection rate of DCIS with digital mammography. Observed trends in rates of DCIS and invasive cancer in initial and successive screenings after the introduction of DM suggest an advance in early diagnosis.
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Poster 'True' interval breast cancers have worse tumour characteristics and survival compared to screen-detected breast cancers, while missed screen-detected breast cancers have not Background: There is debate whether tumours discovered in the breast screening programme after a positive screen examination (screen-detected cancer, SDC) differ from tumours that manifest clinically in the period between two screens after a negative screen examination (<24 months, 'true' interval cancer [IC] ) and from tumours from patients with a positive screen examination, who have a benign assessment in the hospital, but still develop breast cancer within 12−24 months after screen examination (ICafter-positive-screen). We aim to identify differences in tumour and survival characteristics of SDC, IC, and IC-after-positive-screen.
Methods: All women (50−75) who underwent a screen examination by the Dutch National Cancer Screening Programme, region North between 2004 and 2008 were selected and data were merged with data of the Netherlands Cancer Registry. SDC (diagnosed <12 months after a positive screen), IC diagnosed <12 months (IC<12m) or 12−24 months (IC12−24m) after a negative screen, and IC-after-positive-screen were identified. Tumour characteristics of each group were compared with the SDC using chi square tests. Differences in survival between groups were analysed with multivariable cox regression, corrected for differences in tumour characteristics.
Results: In total 4472 patients were included, 3363 with SDC, 501 IC<12m, 861 IC12−24m and 48 IC-after-positive-screen. Screendetected cancers, compared to IC<12m and IC12−24m respectively, were more often of the ductal type (84% vs. 76% and 77%), well differentiated (28% vs. 17% and 15%) and hormone receptor positive (77% vs. 71% and 67%). SDC had less often T2+ (17% vs. 44% and 50%), positive lymph nodes (28% vs. 51% and 45%) or metastasis (1% vs. 5% and 4%). IC-after-positive-screen were not different compared to SDC for all these factors. In total 608 women (13%) died. No difference in survival was found for IC<12m (HR 0.86, 95% CI 0.66-1.12) and IC-after-positive-screen (HR 1.40, 95% CI 0.58-3.39) compared to SDC. Women with an IC12−24m had worse survival (HR 1.44, 95% CI 1.17−1.77).
Conclusions: 'True' IC had less favourable characteristics than SDC. IC-after-positive-screen had the same characteristics and could have the same prognosis as SDC. It has to be determined why these cancers were missed in the hospital. Only women with an IC12−24m had a worse survival compared to SDC. Rates and difference between rates (DR) in women with and without previous benign invasive procedure, and 95% confidence intervals (95% CI) were calculated for all breast cancers, and according to mode of detection and type of invasive test.
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Results: An overall of 6,652 breast cancers were detected in successive screenings. Of them 215 presented previous benign invasive procedure. Rates of women who developed a breast cancer were higher among those with previous benign invasive procedure than among those without (11.1‰, 95% CI = [9.6-12.6] vs. 5.0‰ Conclusions: Results showed that previous benign invasive procedures increase breast cancer detection in subsequent screenings, which suggests the suitability of this factor into future screening strategies based on individual risk. Further studies are needed to explore these differences considering the time between the invasive procedure and cancer diagnosis, and tumour characteristics.
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Poster Hormone therapy and risk of breast cancer Individual exposure information to hormonal treatment was obtained from the Norwegian Prescription Database. Data on incidence of breast cancer was obtained from the Cancer registry of Norway. The unique personal identification number was used to link the databases. The id was encrypted. We studied exposure to estrogen therapy (ET) and the combination of estrogens plus progestin (EPT). The breast cancer incidence rate (BCR) and its 95% confidence intervals (95% CI) were computed. BCR was defined as number of new cases per 1000 women. The crude Relative Risk (RR) and 95% CI of breast cancer risk associated with the use of hormonal treatment was calculated. The referent group were women who did not receive hormonal therapy during the study period.
Results: A total 9 960 incidence breast cancers were diagnosed in the study period. Of these cancers, 1207 were diagnosed among ET users, 1668 among EPT users, and 7 085 among non-users. The BCR for ET users was 8.8‰ (95% CI: 8.3−9.3), for EPT users 16.6‰ (95% CI: 15.8-17.4) and for non-users 10.0‰ (95% CI: 9.7-10.2), respectively. Users of hormone therapy had an overall increased RR compared to non-users of hormone therapy (RR = 1.21 (95% CI: 1.16-1.27). However, the risk differed significantly with different hormone therapies. ET users were at a lower risk for breast cancer than non-users (RR = 0.88 (95% CI: 0.83-0.94), whereas EPT users were at an increased risk for breast cancer (RR = 1.66 (95% CI: 1.58−1.75).
Conclusions: Women taking EPT had an increased risk of breast cancers compared with non-hormonal treatment users. However, ET users had a decreased breast cancer risk. 
Background:
The purpose was to compare rates of women who developed a breast cancer in mammography screening between those with and without previous radiological findings, and to assess the relative risk of cancer detection in subsequent screenings associated to each radiological pattern.
Material and Methods:
Retrospective cohort of 555,285 women aged 50−69 years screened in Spain during 1994 to 2011. Population based screening in Spain is offered every two years. At each screening episode, information of radiological patterns was recorded as, negative, tumour-like mass, distortion, calcification, asymmetry, or other. Rates of women who developed a breast cancer was defined as breast cancers detected among 1000 mammograms in successive screenings, or during screening interval (tumours diagnosed after a negative screening mammogram and before the following screening). Cancer rates and 95% confidence intervals (95% CI) were calculated. The relative risk (RR) and 95% CI of cancer detection associated to each radiological pattern were calculated. The referent group was women without previous radiological patterns in screening mammograms.
Results: An overall of 6,652 breast tumours were detected in successive screenings. Of them 4,284 presented radiological patterns in previous screening mammograms. Rates of women who developed a breast cancer were higher among those with radiological patterns in previous screening mammograms than among those without [8.4 (95% CI 8.0−8.7) vs. 4.2 (4.1−4.3), respectively; RR = 2.0 (95% CI: 1.9−2.1)]. The radiological pattern associated with the highest relative risk of subsequent cancer detection was distortions [RR = 3.2 (2.6−3.9)], followed by microcalcifications [RR = 2.4 (2.3−2.6)], tumour-like mass [RR = 2.0 (1.9−2.1)], asymmetry [RR = 1.9 (1.7−2.1)], and others [RR = 1.3 (1.1−1.6)]. Specifically, the RR of cancer detection in subsequent screenings was 2.1 (95% CI: 2.0−2.2) and for interval cancer 1.8 (1.6−2.0).
Conclusions: Women with previous radiological findings were more likely to be diagnosed of breast cancer in subsequent screenings, both for screen-detected and interval cancer. Distortion presented the highest risk of subsequent cancer detection followed by microcalcifications. Further studies are needed to explore these differences considering the additional assessments performed after a radiological suspicious. Results: For all patients diagnosed with metastases, advanced age ( 70 years) and abstinence of systemic therapy proved prognostically unfavourable. In patients with metachronous metastases, disease-free interval <1 year and the occurrence of prior or simultaneous extracranial metastases were associated with poor survival. Molecular subtype did not reach statistical significance in the multivariate analysis.
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Conclusions: Age and provision of systemic therapy constitute prognostic factors for survival in both synchronous and metachronous CNS metastases. The prognostic value of therapy may be subject to selection bias by exclusion of frail patients. In metachronous CNS metastases, the presence of extracranial metastases and the disease-free interval have additional prognostic value. Retrospective studies may significantly contribute to answering survivorship issues for rare tumor types or subgroups of patients. The biological background and different pathological aspects of BRCA1-associated tumors support the hypothesis that patients carrying a BRCA1 and/or BRCA2 germline mutation, a relatively rare characteristic, might have a worse breast cancer prognosis compared to non-carriers. However, studies showed inconsistent results. We performed a systematic review taking into account the quality of all relevant studies published so far on BRCA1/2 mutation carriership and survival (n = 66). Using a best-evidence synthesis, we found that there is only moderate evidence for a worse unadjusted recurrence-free survival for BRCA1 mutation carriers compared to non-carriers and lack of evidence for all other outcomes. Results were heterogeneous due to differences in study design, study size, study populations and methodological quality.
We compared these findings to those of our own study including invasive pathologically-confirmed breast cancers, diagnosed before <50 years of age, in the period 1970-2002, in ten Dutch centers, in patients with no previous malignancies. In this retrospective study, DNA for BRCA1/2 analyses was isolated from formalin-fixed, paraffin-embedded tissue blocks containing normal (non-tumor) tissue; hence including all patients with tissue blocks without any selection for survivorship or family history. Most frequently occurring BRCA1/2 mutations were analyzed using Taqman PCR and fragment length analyses and confirmed by direct sequencing, capturing~70% of all Dutch pathogenic mutations. We found 3.6% BRCA1 and 1.2% BRCA2 mutation carriers among 5391 breast cancer patients. BRCA1/2 carriers who were identified by the clinical genetic center had a better survival (30% at 10 years follow-up; overall survival, unadjusted) than BRCA1/2 carriers who were only identified by our study.
Comparing our study with earlier studies, we will clearly demonstrate that e.g. survivor bias, and selection through clinical genetic centers contribute to the heterogeneity of findings among studies in BRCA1/2-carriers. In addition, we observed time dependency of BRCA1/2 mutation status in our study, comparable to that reported earlier for estrogen receptor status, something not reported by any other study so far.
The presentation will provide an overview, including examples of typical bias issues, of the evidence of worse survival in BRCA1/2 carriers, and the relationship with tumor subtypes. As such it will also illustrate issues that are relevant for any retrospective analyses of (trial) data to answer survivorship issues. Background: According to current knowledge brain metastases (BM) cannot be predicted. However, HER 2 over expression is notorious for predisposing breast cancer patients for BM, either as a first or subsequent metastatic site. The aim of this analysis is to evaluate incidence of BM as a first metastatic site, among HER2 3+ BC patients and to explore their characteristics. Better knowledge of these characteristics might help in defining a subgroup of patients in whom BM screening is most justified. Actually, because there is no recommendation for routine BM screening it is not well explored whether earlier diagnosis and BM directed treatment, could influence survival. HER2 status of the primary BC was known for 206 pts (89.5%), and HER2 3+ BCBM is registered in 73 pts (31.7 %). Total 62 pts (85%) received trastuzumab as adjuvant/neoadjuvant (27%) or systemic treatment (73%). BM were confirmed by brain CT/MR.
Results: BM as a first and sole metastatic site is registered in 24/73 HER2 3+ pts (32%), median 20 months after BC diagnosis (Table 1) ; 25% (6/24) of those pts developed BM during adjuvant treatment (EBC); 75% (18/24) during treatment for locally advanced BC (LABC). Median number of adjuvant/neoadjuvant trastuzumab was 7 (7−14). Brain surgery was performed in 12 patients, 6 for BM located at the cerebellum. All patients also underwent WBRT. Survival after BM is median 6 months. Background: Racial disparity in breast cancer survival persists globally and a belief exists that black women tend to have more advanced, more aggressive disease. We aim to determine whether the tumour biology varies significantly with race.
Methods: This was a review over a one-year period of consecutive patients diagnosed with an invasive or in-situ breast malignancy in an uninsured population. Data from radiological reports and histology was recorded in addition to demographics including age and race. Tumour characteristics between races were compared, particularly with reference to black patients.
Results: 334 patients had a new diagnosis of breast malignancy. 309 patients had an adenocarcinoma including 292 invasive ductal carcinomas, 12 lobular carcinomas and 13 patients had ductal carcinoma in situ. Other malignancies were 5 lymphoma and 7 sarcoma patients. The median age at diagnosis was 55.
65.3% (218) of patients presenting with a breast malignancy were black. The remaining 116 patients were white (17.1%), asian (6.9%), coloured (5.7%) and unknown (5.1%)
In a comparison of invasive adenocarcinoma patients with known race only (n = 314), 86 patients with malignancy were below 45 years: 32.8% of black patients and 18.7% of non-black patients (p = 0.0378). 38.9% (84 of 218) black patients and 29.2 %(28 of 96) non-black patients had a grade 3 tumour (p = 0.1789). Overexpression of HER2 receptors was found in 63 (20.1%) of all invasive adenocarcinomas; in 19.3% (n = 42) of black patients and 21.9% (n = 21) of non-black patients (p = 0.7264). 52 (16.6%) patients were diagnosed with triple negative malignancies including 17.0% of black patients and 15.6% non-black (p = 1.000).
Conclusion: Our experience suggests there is a relationship between race and a younger age at presentation, but our evidence does not support a link between race and biologically aggressive tumours, with none of the three surrogate markers for aggression significantly more common in our black patients.
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Poster CDH1 and genetic predisposition to lobular breast carcinoma Background: Invasive lobular breast cancer (ILC) and lobular carcinoma in situ (LCIS) are characterised by loss of E-cadherin expression, an adhesion molecule encoded by the CDH1 gene. However germline CDH1 mutations are rare in cases of ILC with no family history of diffuse gastric cancer (DGC) and have not been described in women with LCIS. The aims of this study were to: 1. assess the frequency of rare genetic variants in CDH1 in lobular breast cancer 2. assess whether common polymorphisms within CDH1 predispose to lobular breast cancer Materials and Methods: Germline DNA was extracted from peripheral blood samples collected in the GLACIER (Genetics of LobulAr Carcinoma In situ in EuRope) Study, MREC 06/Q1702/64, which has ascertained patients from throughout the UK with the aim of understanding genetic predisposition to LCIS and/or ILC.
Rare genetic variants were identified by screening the entire coding sequence and associated splice sites of the CDH1 gene by Sanger sequencing in 50 cases of bilateral LCIS/ILC as these cases are more likely to have an inherited component to their disease. MLPA was also performed in order to identify any large scale deletions.
Common genetic variation was assessed in CDH1 by genotyping 52 SNPs that capture the majority of the common genetic variation across the gene using a combination of an Illumina custom array (iCOGS chip) and Taqman in 2500 cases and 3000 controls.
Results: Sanger sequencing of CDH1 in 50 cases of bilateral lobular carcinoma revealed four pathogenic germline mutations, including a novel splicing mutation (c.48+1G>A). The remaining three have been previously described (c.1465insC, c.1942G>T, c.2398delC). All four cases developed bilateral LCIS +/− ILC under 51 years of age and had no family history of gastric cancer. No large scale deletions with MLPA were detected.
There was no evidence of an association with lobular cancer for any of the 52 SNPs genotyped at P < 0.05. This included rs35187787, which is relatively rare (MAF = 0.008) and predicted to be potentially pathogenic (Fisher's exact, p = 0.58).
Conclusion: Rare variants in CDH1 are more common than previously described when bilateral cases of ILC or LCIS are selected for analysis. This has implications for the current guidelines on CDH1 testing in clinical practice, which require a family history of DGC before CDH1 screening can be offered to a patient with ILC.
In contrast common polymorphisms in CDH1 do not appear to predispose to lobular breast cancer.
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Poster Costs of hospital care over ten years from diagnosis of early breast cancer in England 
Sheffield, United Kingdom
Background: Improvements in the efficiency of healthcare are dependent on data describing the costs of care. The costs of breast cancer care to healthcare providers are poorly reported. This is particularly the case for clinical events beyond initial diagnosis. We therefore used new techniques in data linkage to report the costs of care for a cohort of patients with a new diagnosis of breast cancer. We include the costs following cancer recurrence and the costs of care at the end of life. Methods: 1,000 consecutive patients diagnosed with breast cancer (ICD10 C50) from January 1999 were identified from the electronic clinical record of a large cancer centre and the Northern and Yorkshire Cancer Registration and Information Service (NYCRIS). Eligible patients were followed up for minimum of 10-years or until death if earlier, and had complete data linkage. Baseline demographics, clinical characteristics, treatment date and type of recurrence and date of death were available and were verified by 100% clinical audit. Linked data was obtained from the local NHS finance records to provide details of hospital resources used and the costs of care based on the NHS England Payment-By-Results national tariff. Costs are reported in 2011 GBP.
Results: There were 484 eligible patients. The mean 5 year cost from diagnosis was £9,961 (95% CI 9,219-10,718) and the mean 10 year cost from diagnosis was £14,220 (95% CI 13,017-15,464). The mean 10 year cost in patients with no observed recurrence was £12,443 (95% CI 11,504-13,411) compared with £19, 706 (95% CI 16, 480) in patients with an observed recurrence. The mean 5 year cost from recurrence was £13,308 (95% CI 10,644-16,480) in the 182 with an observed recurrence events. The cost fell from a mean of £3,232 over the first 3 months from diagnosis to plateaux at around £250 per 3 month period from 18 months onwards. The mean cost of care for the final 30 days of life was £1,050 (95% CI 839-1,288) in the 364 patients who died.
Conclusions: The costs of hospital care for breast cancer falls rapidly over the first 18 months from diagnosis. Cancer recurrence places an additional financial burden on the hospital which is of a noteworthy magnitude. Investment in the prevention of recurrence should be a priority for financial as well as clinical reasons. The costs of care during the endof-life phase of breast cancer should also be taken into account.
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Poster Genomic alterations, biochemical analysis and association of BRCA1 and BRCA2 gene polymorphism in hereditary breast cancer patients in South Indian population Background: Breast cancer is the second most common cancer in India. Epidemiological studies on breast cancer have largely focused on risk factors such as age at menarche, menopause and reproductive history and religion, little or no report exist on familial breast cancer or mutations in breast cancer predisposing genes even though genetic predisposition is likely responsible for 5−10% of all breast cancers. BRCA1 and BRCA 2 is a highly penetrate gene that contributes an estimated 56−85% lifetime risk of developing breast cancer. The Objective of the present study was to evaluate the Genomic alterations, Biochemical analysis and Association of BRCA1 and BRCA2 Gene Polymorphism in Hereditary Breast Cancer Patients in South Indian Population.
Methods: Peripheral blood samples were obtained from 42 Breast cancer patients and 42 Healthy controls were investigated by means of Conventional Cytogenetic analysis using Giemsa Trypsin Giemsa (GTG) banding, Genetic Alteration were confirmed using Florescence in Situ Hybridization. Biochemical Serum GSH, GST and NO levels were estimated by spectrophotometric methods. BRCA1 and BRCA2 gene polymorphism were carried out using Restriction Fragment Length Polymorphism analysis.
Results: Breast cancer cases showed Higher Frequency of Genomic instability (p < 0.001) compared to controls, Florescence in Situ Hybridization showed frequent Chromosomal Aberrations, largely involve the loss of 17p and the gain of 6q were confirmed. In comparison with Breast cancer patients, the control subjects exhibited very low levels of major CA (P < 0.05). The serum level of reduced glutathione, GST and NO
• were significantly higher (P < 0.0001) breast cancer patients before chemotherapy as compared to healthy controls. BRCA1 and BRCA2 Gene polymorphism showed a significant association in Hereditary breast cancer patients when compared to controls.
Conclusions: Chromosomal instability and Biochemical alterations proven to be a potential biomarker for Breast cancer susceptibility. While the molecular genetic events associated with the initiation and progression of Breast cancer remains poorly understood, it has long been considered that genetic instability plays a pivotal role in the development and progression of human cancer, and as with most types of human cancer, multiple genetic changes are probably necessary for Breast carcinogenesis. Identification and understanding of critical molecular pathways leading to cancer progression gives some fresh prospective in development of novel and more effective therapies for Breast cancer. Results: Breast cancer cases showed a Higher Frequency of Chromosomal instability (p < 0.001) compared to controls, Few cases showed characteristic genetic alteration in chromosome 3p, 6q, 9p, 10q, 11q, 16q, 16p, 17p and X. Elevated frequency of Biochemical alteration showed statistically significant (p < 0.001) in Breast cancer patients compared to controls. Drug metabolizing gene polymorphism (CYP1A1 and GSTM1) showed a significant association in breast cancer patients when compared to controls.
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Conclusions: Conventional cytogenetic analysis play a major role in early diagnostic screening of Breast Cancer Patients. MDA, LOOH, and PC could be used as important biochemical Antioxidant parameter for differentiation and progression of breast cancer with and without metastasis, which are cost effective, and can be easily assayed in smaller laboratories. Thus the study provides an evidenced based data, which indicates a increased risk for Breast cancer in individuals carrying the mutation in CYP1A1 and GSTM1. Cytogenetic Analysis remains the first choice and backbone for laboratory investigation in cancer research. Its usefulness in initial diagnosis as well as in monitoring the therapy. Thus, more ongoing cytogenetic analysis along with molecular cytogenetic will allow better evaluation of the genomic aberrations involved in Breast Cancer, and will offer a new directions for further molecular investigation.
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Poster Worse event-free and relapse-free survival in financially disadvantaged patients with breast cancer in South India Introduction: Economic disparity affects the treatment and hence the outcome of malignancies. We for the first time in South India have attempted to quantify the effect of inadequate financial resources on the outcome of patients with breast cancer who have visited our center.
Materials and Methods:
Retrospective and prospective data collection was done for all the patients who visited the breast cancer clinic of Global Cancer Institute, Bangalore, between January 2012 and August 2013. Affordability for treatment is decided during the first patient visit. If patients had financial resources of about Rupees 400,000 this was deemed to be sufficient for appropriate multidisciplinary treatment. The usual sources of funding are self-funding, health insurance and for some patients, funding via various Government and employer-funded schemes.
Events were defined as death and relapse. Results: Out of the 182 patients who visited our clinic in this time period, 119 were diagnosed to have breast cancer. There were 118 (99.2%) female patients and 1 (0.8%) male patient. The median age was 51 years (range 17−84 years). 57 (47.9%) did not have adequate funding for treatment.
Patients who did not have adequate funding for treatment were similar to those who had adequate funds for treatment except that, a greater number of non-affording patients had extensive intraductal component (5.26% vs. 1.61%, p = 0.028) as well as perinodal spread (33.3% vs. 17.74%, p = 0.004).
S81
A greater number of patients who had limited funding received 6 cycles of FAC (5-FU, adriamycin and cyclophosphamide) (57.7% vs. 17.6%, p = 0.000) as opposed to 8 cycles of epirubicin cyclophosphamide/ adriamycin cyclophosphamide with docetaxel/paclitaxel (7.7% vs. 47.1%, p = 0.000), which were given to those who had adequate funding for appropriate treatment.
Among the non-affording and affording patients, the 2-year overall survival was 91.7±8% vs 93.9±4.2% (p = 0.5), the 2-year event-free survival was 28.9±21.7% vs 94.3±3.9% (p = 0.049) and the 2-year relapse-free survival was 32.2±23.9% vs. 97.4±2.6% (p = 0.024), respectively.
Conclusion: Economic disparity has a statistically significant decrease in the relapse-free and event-free survival in patients with breast cancer in South India. Availability of adequate financial resources might improve the outcomes of the treatment of these patients.
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Poster Breast cancer in South-Eastern European countries: Rising incidence and decreasing mortality at young and middle age Background: Most South-Eastern European countries share common political, socio-economic and demographic changes i.e. increased longevity, low but rising age at childbirth, decreased fertility rates, adoption of some 'western' life style patterns e.g. increasing alcohol and tobacco use among younger women, and rapid diffusion of mammography in the context of screening. From a previous study, in the scope of EUROCOURSE (http://www .eurocourse.org/), breast cancer incidence and mortality trends for 1999-2008 appeared to vary: increasing incidence in most of them and a steady fall in breast cancer mortality, not yet convincing in Serbia and Bulgaria. Analysis of trends by age groups may unravel variations by age groups and address more specific issues.
Materials and Methods: We analyzed data from 11 cancer registries, situated mostly in South-Eastern European countries, but also in westTurkey, Malta and Cyprus. Age-standardized (world standard) and truncated age-standardized incidence and mortality rates for the period 2000-2010 (or for the most complete recent period) by year and by age groups were calculated, based on corresponding regional or national cancer registries, some of them only recently started. Average annual percent change of rates was estimated using joinpoint regression.
Results: Annual incidence was generally increasing statistically significant by 1 to 3% (all ages), by 2 to 4% (15−39 years), 4 to 5% (40−49), 1 to 4% (50−69) and 1 to even 6% (at 70+). Mortality was decreasing statistically significant by −2 to −4% (all ages), −5% (15−44, for Bulgaria), −3 to −5% (45−54, for Czech Republic and Serbia), −2 to −4% (55−74, for Slovenia, Romania/Cluj and Czech Republic), −3% (75+, for Czech Republic), annually. Mortality was increasing statistically significant by 2% above age 55 in Serbia and by 5% for 75+ in Cyprus, annually.
Conclusions: The observed variations of incidence trends by countries and age groups reflect the influence of risk factors, as well as level of early diagnostic activities (screening), especially for 50+ age groups. Effects of organized or opportunistic screening for this age group − increasing incidence and decreasing mortality, was seen for Czech Republic, Romania/Cluj and Slovenia. The favorable trend for decreasing mortality in other age groups was probably due to better staging and improved therapy, but still there were worrying trends for increasing mortality in 55+ age groups in Serbia and Cyprus. These results may serve to health professionals and policy makers concerning breast cancer control in the corresponding countries. Background: In recent years, it has often been observed that old age is associated with less aggressive treatment of primary breast cancer (PBC), regardless of the stage. Relying on our material, we investigate whether our therapeutic approach in women >75 years was 'strictly' adhering to protocols.
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Material and Methods: We examined, retrospectively, the records of 134 women over 75 years of age relating to cases of primary breast cancer, operated in our Department, in the period 2009-2011. The average age was 77.4 years (75−89 years).
In our study, we seek data regarding to the epidemiological features of our patients, as well as the histo-pathological and immune-histochemical findings of their surgically removed tumors. Also, the type of surgical technique performed and the adjuvant treatment that our patients received, are analyzed and compared to international guidelines.
Results: In the age group of women over 75 years with PBC, there seems to be a positive correlation between age and less aggressive biological tumor characteristics, including hormonal receptors positive expression, the grade of the tumor, the c-erbB2 negative expression etc. Also, as far as the whole therapeutic treatment is concerned, it seems that in the majority of women under 80 years, international protocols were followed to the letter, while for the majority of the group of patients above 80 years, more conservative treatment was followed.
Conclusions: In women above 75 years, the less aggressive characteristics of PBC, allow for more conservative treatment of these women, without changing life expectancy or morbidity, especially in the age group above 80 years. Background: BRCA1 and BRCA2 are the two major breast cancer susceptibility genes. Approximately 25−50% of hereditary breast cancer cases can be explained by mutations in these two highly penetrant genes. BRCA1-associated breast cancers are often triple negative, with high mitotic count and high histological grade, characteristics associated with poor prognosis. BRCA2-associated breast cancers are also of higher histological grade than sporadic breast cancers although the difference is less pronounced as compared with BRCA1-associated cancers. The clinical course of patients with breast cancer who live in Cyprus and harbor BRCA1/2 mutations has never been examined collectively before. The aim of this study was to examine the patterns of relapse as well as the survival of breast cancer patients with BRCA mutations living in Cyprus. Materials and Methods: A total of 50 breast cancer patients that were tested positive for the BRCA1 or BRCA2 genes and were treated and followed-up at the Bank of Cyprus Oncology Center were included in this study. So far in Cyprus, 60 patients with breast cancer were found positive for the BRCA1/2 genes, hence our current analysis covered a large proportion of this group of patients. A retrospective review of medical records was conducted in order to determine clinical characteristics and follow-up data including BRCA mutation status, patterns of relapse and event free survival.
Results: Out of the 50 BRCA1/2 carriers included in this study, 18 developed a relapse whereas the remaining 32 remain disease-free. Among the 18 relapses, 4 were new ovarian cancers, 5 patients developed metastatic disease and 9 patients had either a contralateral or ipsilateral breast cancer. A trend was noted towards a more favorable outcome for BRCA2 mutationcarriers compared to BRCA1 mutation carriers with fewer relapses (31% vs. 55%) as well as a longer time to first relapse. Only 5 women (10%) died of the disease while only another 5 (10%) are currently treated with metastatic disease. Overall, 80% of the breast cancer BRCA mutation carriers included in our study are well, alive and disease free despite their advanced disease and their unfavorable histological type. It is noted that all patients included in our study lived for at least 5 years following their diagnoses.
Conclusions: Despite the small number of patients included in our study, our results confirm that BRCA1 carriers have worse disease-free survival rates compared with BRCA2 mutation carriers. It appears that overall survival and disease-free survival rates among women with BRCA1/2 mutations are higher than anticipated according to their stage and grade.
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Poster Age effect on treatment decision for adjuvant chemotherapy in women with ER-positive early breast cancer: Analysis of the basic data of the POCHARBI trial, an observational study conducted by the Hellenic Society of Breast Surgeons Analysis of the baseline data gave us the opportunity to observe factors influencing the decision for adjuvant chemotherapy in an ER-positive Early Breast Cancer patients' population in a 'real life' clinical setting.
Material and Methods:
This was a 12 month, multicenter, observational study of women in postmenopausal status, with ER-positive early breast cancer, treated with an AI either as first line therapy or as maintenance therapy after initial treatment with anthracycline-and/or taxane-based CT. Lumbar spine (LS) and total hip (HP) bone mineral density (BMD) were measured before and after CT and at the end of a follow up period of 12 months after AI initiation. Ethical approval was obtained prior to study initiation (NCT01298362).
Results: A total number of 290 patients included in the study: 124 patients in the CT+HT arm and 166 patients in the HT arm. Mean age in the CT+HT group was 61.2(10.2) and in HT group 66.2(9.2) years. Tumor stage (TNM) and Grade were, as expected, the major decision making factors for treating women with CT. However, post-hoc analysis indicated also, that patient's age was an additional factor which influences physicians' decision to use chemotherapy. Patients' group of 40−60 years old received significantly more CT than the 60−70+ years group (Table 1) .
Conclusions: Post hoc analysis on the baseline characteristics of the population of this study indicated that Age is an independent factor, which influences physicians in Greece, to decide on using adjuvant chemotherapy in post-menopausal patients with ER-positive, early breast cancer. Despite international guidelines, elderly patients receive less chemotherapy than younger ones with the same treatment characteristics. Background: Breast cancer is characterized by its molecular and clinical heterogeneity. The current study focuses on assessing how risk factors relate to molecular subtypes. Patients and Methods: A total of 507 female patients with breast cancer who have been followed up at NCI and Nasser institute during the period from July 2012 till February 2013 were included and categorized into 5 molecular subtypes by immunohistochemistry. Case-case odds ratios comparing risk factors across tumor subtypes using the luminal A tumors as the reference group were estimated.
Results: Three hundred and twenty one patients had luminal A, 73 had luminal B, 66 had Her2-overexpressing, 30 had basal like and 17 had unclassified breast cancers. We observed significant differences in biological subtypes for the distribution of residence (p 0.001), age at diagnosis (P = 0.016), number of full term births (P = 0.028) and history of contraception use (p = 0.026). The age of 35 years was found to be a risk factor for unclassified tumors (OR: 5.16, 95% CI: 1.68-15.85; P = 0.008 compared with luminal A), similar to Luminal B and HER2 expressing cases (p = 0.087 and 0.045 compared with Luminal A respectively). Rural residents were more likely to be unclassified cases (OR: 7.97, 95% CI: 2.53-25.07; P 0.001 compared with luminal A). Nulliparous women had an increased risk of unclassified tumors (OR: 5.22, 95% CI: 1.53-17.83 p = 0.008 compared with Luminal A), while women who had 2 children were found to be at high risk for Luminal B (OR: 3.241, 95% CI: 1.48-7.09; P = 0.003 compared to Luminal A). Premenopausal patients were associated with increased risk of unclassified breast cancer (OR: 3.43, 95% CI: 1.28-9.24; p = 0.015 compared with Luminal A) whereas, no significant difference were found for other subtypes. Patients with history of combined estrogen and progesterone contraception use were associated with a significant increased risk of unclassified tumors (OR: 0.1, 95% CI: 0.02-0.54; p = 0.004) while no protective association was seen against other biological subtypes. We observed that compared with the predominant luminal A tumors, association with age at menarche, education, age at first full term birth, family history of breast cancer and BMI showed no significant difference with biological subtypes.
Conclusion: Results from this study have shown that luminal A and unclassified tumors seem to have distinct sets of risk factors, suggesting etiologic, in addition to clinical, heterogeneity.
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Poster Barriers to uptake of breast cancer screening in Western Kenya Introduction: In October-November 2012 we conducted clinical breast cancer screening open to both men and women in three sites in western Kenya. One week before the events, posters, community meetings and word of mouth through community health workers publicized the screening events. Although there were substantial turnouts, we wanted to explore community-level perceptions of barriers to screening uptake to plan future events. Methods: After screening, we surveyed community members (18 years and older) who did not attend the breast cancer screening events in the targeted communities. A recruitment questionnaire was used to identify the target group. Both structured and open-ended questions were used to collect data at the household level. Descriptive and content analyses were performed.
Results: A total of 733 community members were surveyed (63% women, median age 33 years, IQR = 26−43). Women and men respondents did not differ significantly in their responses. 55% of respondents had heard about the breast cancer screening but did not attend. There were no significant socio-demographic or socio-economic differences between those who knew about the screening and those who did not. Similarly, there were no significant differences in perceived barriers to screening including; potential embarrassment (3%), fear of outcome (4%), and negative influence of significant others (5%). A higher percent of those who had heard about this particular screening event reported knowing about breast cancer screening services in general (45% vs. 25%, p = 0.001). Only 8.0% of those who heard and 6.0% of those who had not heard
